BUKWANG PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Yoo, Hee Won
Um, Jung Yoon
Jun, Hun
Abrégé
The present invention relates to a treatment agent for a coronavirus, and, more specifically, to a use for the purpose of treating coronavirus infection by administering a drug or a pharmaceutical composition comprising L-nucleoside represented by chemical formula 1.
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61P 31/14 - Antiviraux pour le traitement des virus ARN
BUKWANG PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Lee, Kwang Ok
Lee, Kyung Hwa
Jeong, Eun Ju
Abrégé
The present disclosure relates to a method for preparing tolimidone on large scale with maintaining high purity and uniform particle size distribution, and more specifically, a method suitable for preparing tolimidone on industrially large scale by using tetrabutyl ammonium bromide catalyst and recrystallization in ethanol, which can prepare highly pure tolimidone in a time shorter than prior arts while maintaining water content and particle size distribution constantly.
BUKWANG PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Lee, Kwang Ok
Lee, Kyung Hwa
Jeong, Eun Ju
Abrégé
The present disclosure relates to a method for preparing tolimidone on large scale with maintaining high purity and uniform particle size distribution, and more specifically, a method suitable for preparing tolimidone on industrially large scale by using tetrabutyl ammonium bromide catalyst and recrystallization in ethanol, which can prepare highly pure tolimidone in a time shorter than prior arts while maintaining water content and particle size distribution constantly.
BUKWANG PHARMACEUTICAL CO., LTD. (République de Corée)
Inventeur(s)
Lee, Jun
Lee, Young Hun
Park, Byung Sun
Yoo, Hee Won
Abrégé
Disclosed are: a compound of chemical formula 1; a pharmaceutically acceptable salt or stereoisomer thereof; and a pharmaceutical composition containing the same. The compound of chemical formula 1 or the pharmaceutically acceptable salt or stereoisomer thereof acts as a multi-target kinase inhibitor, thereby being usable in the prevention or treatment of cancers or immune-related diseases such as rheumatoid arthritis, Sjögren's syndrome, psoriasis, systemic lupus erythematosus, atopy, asthma and multiple sclerosis.